A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging
Open Access
- 29 September 2026
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5704-5717
Abstract
Targeted imaging for the extracellular domain (ECD) of epidermal growth factor receptor (EGFR) is promising for early diagnosis and therapeutic applications toward cancers. Herein, we report the design of a γ-AApeptide-based antibody-like peptidomimetic as a radiotracer for EGFR-targeted positron emission tomography (PET) imaging. A dimeric cyclic γ-AApeptide (D1) was designed by dimerizing a previously reported EGFR-binding peptidomimetic ligand, resulting in a 6-fold enhancement in binding affinity (Kd = 0.11 μM) compared to its monomeric counterpart (M1, Kd = 0.67 μM). Both ligands were conjugated with chelators and radiolabeled with 64Cu to yield [64Cu]Cu-NOTA-M1 (monomer) and [64Cu]Cu-DOTA-D1 (dimer), respectively. In vivo PET imaging demonstrated that [64Cu]Cu-DOTA-D1 achieved significantly higher tumor uptake than [64Cu]Cu-NOTA-M1 in EGFR-positive tumor models (e.g., 10.83 ± 2.70 %ID/g vs 2.80 ± 0.72 %ID/g in U87 tumors at 4 h p.i.). Blocking and EGFR-negative control studies further confirmed the targeting specificity of [64Cu]Cu-DOTA-D1. Ex vivo biodistribution analysis showed consistent enhancement in tumor uptake (e.g., 7.94 ± 0.24 %ID/g vs 3.81 ± 0.44 %ID/g in U87 tumors at 48 h p.i.) for the dimeric tracer, accompanied by increased uptake in clearance organs. Overall, this work demonstrates that cyclic γ-AApeptides could serve as effective antibody-like peptidomimetics for EGFR targeting in vivo and provides a versatile strategy for developing peptidomimetic radiotracers for molecular imaging applications.Keywords
Funding Information
- University of Wisconsin-Madison (P30 CA014520)
- National Natural Science Foundation of China (82404588)
This publication has 52 references indexed in Scilit:
- Photocaged fluorescent probes for spatiotemporally monitoring G-Quadruplex DNA in live cellsBioorganic Chemistry, 2025
- Pharmacokinetic analysis of 6-O-[18F]FEE for PET imaging of EGFR mutationBioorganic & Medicinal Chemistry Letters, 2023
- Preparation of radiolabeled erlotinib analogues and analysis of the effect of linkersBioorganic & Medicinal Chemistry Letters, 2022
- Peptidomimetic-based antibody surrogate for HER2Acta Pharmaceutica Sinica B, 2021
- [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Stabilization of lncRNA GAS5 by a Small Molecule and Its Implications in Diabetic AdipocytesCell Chemical Biology, 2019
- γ‐AApeptides as a New Class of PeptidomimeticsChemistry – A European Journal, 2016
- Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patientsInternational Journal of Cancer, 2012
- Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105European Journal of Nuclear Medicine and Molecular Imaging, 2011
- EGFR-Mutationsanalyse beim nichtkleinzelligen LungenkarzinomDer Pathologe, 2009